Sutro Biopharma Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $182.64 million. The enterprise value is $29.08 million.
| Market Cap | 182.64M |
| Enterprise Value | 29.08M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 16.58 million shares outstanding. The number of shares has increased by 38.81% in one year.
| Current Share Class | 16.58M |
| Shares Outstanding | 16.58M |
| Shares Change (YoY) | +38.81% |
| Shares Change (QoQ) | +26.67% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 66.04% |
| Float | 10.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.97 |
| Forward PS | 4.65 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.32
| Current Ratio | 3.32 |
| Quick Ratio | 3.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.08% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -93.14% |
| Weighted Average Cost of Capital (WACC) | 28.87% |
| Revenue Per Employee | $357,047 |
| Profits Per Employee | -$1.41M |
| Employee Count | 128 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -96,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.26% in the last 52 weeks. The beta is 1.50, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | +40.26% |
| 50-Day Moving Average | 17.95 |
| 200-Day Moving Average | 23.11 |
| Relative Strength Index (RSI) | 24.73 |
| Average Volume (20 Days) | 286,088 |
Short Selling Information
The latest short interest is 1.85 million, so 11.14% of the outstanding shares have been sold short.
| Short Interest | 1.85M |
| Short Previous Month | 2.08M |
| Short % of Shares Out | 11.14% |
| Short % of Float | 17.16% |
| Short Ratio (days to cover) | 5.93 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $45.70 million and -$180.64 million in losses. Loss per share was -$15.47.
| Revenue | 45.70M |
| Gross Profit | -99.04M |
| Operating Income | -131.86M |
| Pretax Income | -180.73M |
| Net Income | -180.64M |
| EBITDA | -125.80M |
| EBIT | -131.86M |
| Loss Per Share | -$15.47 |
Balance Sheet
The company has $164.35 million in cash and $10.78 million in debt, with a net cash position of $153.56 million or $9.26 per share.
| Cash & Cash Equivalents | 164.35M |
| Total Debt | 10.78M |
| Net Cash | 153.56M |
| Net Cash Per Share | $9.26 |
| Equity (Book Value) | -103.32M |
| Book Value Per Share | -6.23 |
| Working Capital | 122.75M |
Cash Flow
In the last 12 months, operating cash flow was -$145.17 million and capital expenditures -$446,000, giving a free cash flow of -$145.62 million.
| Operating Cash Flow | -145.17M |
| Capital Expenditures | -446,000 |
| Depreciation & Amortization | 6.06M |
| Net Borrowing | n/a |
| Free Cash Flow | -145.62M |
| FCF Per Share | -$8.78 |
Margins
| Gross Margin | -216.71% |
| Operating Margin | -288.52% |
| Pretax Margin | -395.46% |
| Profit Margin | n/a |
| EBITDA Margin | -275.25% |
| EBIT Margin | -288.52% |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.81% |
| Shareholder Yield | -38.81% |
| Earnings Yield | -99.58% |
| FCF Yield | -80.28% |
Analyst Forecast
The average price target for Sutro Biopharma is $47.23, which is 328.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.23 |
| Price Target Difference | 328.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | -37.15% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Sutro Biopharma has an Altman Z-Score of -8.38 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.38 |
| Piotroski F-Score | 2 |